Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Dunad Therapeutics, a UK-based developer of protein degradation technology, launched yesterday with £5m ($7m) in funding from venture firm Epidarex Capital. Dunad advances research by co-founder, acting chief executive and chief scientific officer Prof Patrick Gunning, a researcher in University of Toronto Mississauga’s Department of Chemical and Physical Sciences. Inotec AMD, a UK-based wound healing…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.